Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Serono Taps Aussie Biotech For New MS Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Licensing deal includes up to $47 million per developed drug and full research funding.

You may also be interested in...

Infections, Death Fail To Stop Novartis’ Phase III MS Trial

“Confounding” factors in play; monitoring board gives green light to continue.

Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says

Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.

Novartis’ Oral MS Drug Strong In Three-year Phase II Data

Side effects rang alarms early on, but disappeared over time.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts